GLP-1 Is Reshaping the Bodies of Customers. Is Your Sizing Strategy Ready?

Two years ago, we analyzed body measurement data across 18 million shoppers to assess whether GLP-1 medications were visibly shifting how Americans size. At the time, our data told a clear story: not yet.

That finding made headlines. But we also said something else: watch this space.

The space has changed.
 

From a Healthcare Story to a Retail Planning Problem

GLP-1 adoption has not trickled into apparel. It has accelerated into it.

U.S. adoption grew from 11% of shoppers in late 2024 to 16% by the end of 2025, according to Bernstein's annual survey of 4,000 U.S. consumers, before oral pill forms hit the market. JPMorgan estimates the number of Americans on GLP-1 treatment will triple to 30 million by 2030 [JPMorgan, 2026]. Circana puts current household penetration at approximately 23% of all U.S. households as of September 2025 [Circana, 2025].

This is no longer a niche health trend. It is a structural consumer shift moving faster than most apparel brands are built to respond to.

Bernstein analysts estimate GLP-1-driven wardrobe changes could generate up to $13 billion in incremental annual apparel spending. A typical year of GLP-1 use produces between 20 and 50 pounds of weight loss, or one to five full sizes [Bernstein, 2026]. Eighty percent of GLP-1 users expect to need new clothing as a result [Circana, 2026].

The demand is real. The question is whether your systems can meet it.

The Problem Isn't Just Weight Loss. It's Volatility.

Here is what makes this moment genuinely different from any previous wave of body change: the speed, the scale, and the instability happening all at once.

A customer on GLP-1 today is not on a linear journey. They are losing weight at varying rates. They are purchasing athleisure and stretchy fabrics while in transition, because rigid-fit garments don't work for a body in motion. They may drop three sizes over 12 months. And then, if they discontinue treatment, a new wave of change begins.

Nearly half of GLP-1 users (46.5%) stop taking the medication within 12 months, according to a 2025 study of 125,474 individuals published in the BMJ [BMJ, 2026]. Research from the University of Oxford found that those who stop regain weight steadily, returning close to their original size within approximately 1.7 years [BMJ, 2026].

That is not just a health story. It is a second wave of demand disruption from the same cohort, and most apparel brands have no mechanism to detect it coming.

The real-world picture is already showing up in earnings reports. DXL, the big-and-tall men's retailer, attributed part of its 6% year-over-year sales decline in Q4 2025 to GLP-1 adoption, noting that as many as 25% of its customers are on GLP-1 medication and are actively delaying purchases [TheStreet, 2026]. Torrid reported a 14.3% sales decline in the same period [TheStreet, 2026]. The demand gap is not hypothetical. It is already hitting margins.

At the same time, up to 400 million apparel units could be misaligned with actual demand by 2027, with retailers facing up to $5 billion in margin impact from excess inventory, returns, and markdowns [Retail Unwrapped / Robin Report, 2026].

Why Standard Sizing Systems Were Not Built for This

Every size curve in use today is a bet: that tomorrow's customer base looks roughly like today's. In an era of GLP-1 adoption at this scale and pace, that bet is increasingly losing.

Apparel brands plan 12 to 18 months out. Size curves are built from historical data. Fit blocks are static. There is no efficient loop from real-time market behavior back into product planning, which means by the time demand signals show up in returns or clearance rates, brands have already committed to the wrong inventory.

Circana noted something important in its latest research: GLP-1 users in transition are not simply buying smaller sizes. They are hesitating entirely. Consumer sentiment analysis of nearly 100,000 GLP-1 conversations found that apparel traffic is rising, but conversion is not following suit because shoppers don't know their size anymore and don't want to invest in a wardrobe mid-journey [Clootrack, 2026]. Positive body image sentiment among this group sits at only 48.5%.

Discounting that hesitation is the wrong response. Price cuts don't solve a confidence problem. Accurate, personalized fit guidance does: meeting the shopper exactly where they are, in the body they have today.

What Brands That Get This Right Will Do Differently

The brands that will emerge from this period stronger are not the ones waiting for the volatility to settle. They are the ones building the infrastructure to respond in real time.

That means three things:

Real-time body data at the customer level. Not size curves built from last year's purchases, but living body data that reflects who your shoppers are right now. Bold Metrics' platform captures 50+ body measurements per shopper, creating a continuously updated picture of your customer base as it actually is, not as it was when you finalized your buy.

Personalized fit guidance at the point of conversion. A GLP-1 user who doesn't trust standard size charts needs a better answer than "see our size guide." Virtual Sizer™ and SSC™ provide individualized size and fit recommendations based on each shopper's specific measurements, removing the uncertainty that drives hesitation and abandoned carts.

Population-level insight to inform planning. Apparel Insights® surfaces shifts in size distribution across your customer base before they show up as return spikes or excess inventory. If your size 8 demand is quietly softening and size 4 demand is building, you want to know that during your next buy cycle, not after it.

Coresight Research found that 40% of GLP-1 users specifically say that fit guidance or body measurement tools would be most helpful during their weight-loss transition [Coresight, 2025]. They are telling brands exactly what they need. The brands that listen will earn loyalty that outlasts the drug itself.

The Opportunity Is Still Open. But Not Indefinitely.

Two years ago, the data showed that GLP-1 hadn't moved the needle at a population level yet. Today, the picture is different, and it will look different again in 12 months.

The brands that build real-time fit infrastructure now will be positioned to capture the demand wave when it fully arrives. Those who wait will be managing returns and markdowns after the fact.

GLP-1 is not a passing trend. It is a permanent feature of the consumer landscape, one that will continue to accelerate as oral formulations lower the barrier to adoption and insurance coverage expands. The window to get ahead of it is open. It will not stay open indefinitely.

Ready to understand how your customer base is changing in real time? Explore Apparel Insights® or request a demo to see how Bold Metrics helps brands stay ahead of shifting demand.

Sources

1. Bernstein Research. (2026). U.S. Apparel & Specialty Retail: GLP-1 Impact Analysis. Via SGB Media / MarketWatch.
2. JPMorgan. (2026). GLP-1 Adoption Forecast. Via CNBC, April 2026.
3. Circana. (2026). GLP-1 Consumer Survey. Via CNBC / TheStreet, March–April 2026.
4. West, S. et al. (2026). Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. doi:10.1136/bmj-2025-085304.
5. TheStreet. (2026). GLP-1 Weight Loss Disrupting Fashion Retail Demand. March 29, 2026.
6. Clootrack. (2026). GLP-1 Is Rewriting Retail Demand: Four Purchase Rhythms Retailers Are Missing. Globe Newswire, April 2, 2026.
7. Coresight Research. (2025). GLP-1 Consumer Survey. November 2025. Via Inside Retail Asia, February 2026.
8. Retail Unwrapped / The Robin Report. (2026). GLP-1 Is a Disruption Retailers Aren't Ready For. Podcast, April 2026.
9. McKinsey & Company. (2026). State of Fashion 2026.

Bold Metrics. (2024). Exploring the Ozempic Impact: Bold Metrics' Data Insights. boldmetrics.com/blog.